Tag

septal defects Archives - Carey Danis & Lowe

UCLA SSRI Study Examines Pregnancy & Drugs

By | Lexapro, Paxil, Pharmaceutical litigation, Prozac, Uncategorized, Zoloft

ssri_birth_defectsA UCLA study published in December 2014 examined the use of selective serotonin reuptake inhibitors, or SSRIs, during pregnancy. The researchers used lab mice to observe the effects of SSRI exposure in the womb, and how it impacts adult mice.

They observed that adult mice exposed to the SSRI, Lexapro, experienced a permanent change in serotonin transmission, whereas those adult mice exposed to Prozac in the womb, showed no signs of this permanent change.

The UCLA study examined a new side of SSRIs and pregnancy, one documenting the longterm implications of SSRI exposure in the womb, rather than the immediate.

The immediate implications of SSRI exposure in the womb, to a certain degree, are already known. Children have been born with life-changing congenital birth defects. These birth defects include atrial septal defects, ventricular septal defects, Omphalocele, Craniosynostosis, and persistent pulmonary hypertension of the newborn (PPHN).

Carey Danis & Lowe Can Help

Carey Danis & Lowe is a national law firm with a strong reputation for expertly assisting families through the challenges of recovering losses after a child has been born with SSRI birth defects. Our defective drug lawyers understand the pain and suffering these children and their families endure, and are available to help.

Explore your legal options and compensation eligibility today during a free, no-obligation case evaluation.

Contact Carey Danis & Lowe by phone at 800.721.2519, or submit a confidential personal injury claim form.

We look forward to offering you and your family any assistance that we can.

Carey Danis & Lowe Evaluating Zoloft Cases and Offers an Update on Zoloft Lawsuits in Zoloft MDL No. 2342

By | Pharmaceutical litigation, Uncategorized, Zoloft

Published January 14, 2013 by PR Web

St. Louis, Missouri (PRWEB) January 14, 2013

Zoloft MDL Updates: Zoloft MDL No. 2342 Progresses with Order to Submit Initial Discovery Zoloft Birth Defect CasesZoloft lawsuits have been consolidated into a Multi-District Litigation in the U.S. District Court for the Eastern District of Pennsylvania. Judge Cynthia M. Rufe is presiding over the Zoloft MDL.

As to recent developments in the Zoloft MDL, on January 2, 2013, Judge Rufe sent forth Pretrial Order No. 16. Fundamentally, the Pretrial Order outlines how to deliver responses in the MDL. The court document imparts detailed information as to “the procedure for filing responses to all civil actions that are or become consolidated in MDL No. 2342”.*

The Pretrial Order goes on to supply information on how the defendants, Pfizer Inc., Greenstone LLC, and Pfizer International LLC, shall go about filing a Master Short-Form Answer. In essence, the Master-Short Form Answer and Affirmative Defense is the defendants’ response to the claims of the plaintiffs.

According to the Pretrial Order, the Defendants will only have the opportunity to file one Master Short-Form Answer, and in doing so can address any and all charges made against them in each of the cases consolidated in the Zoloft MDL. As the document will stand as their initial response to allegations, Pfizer and Greenstone can deny the plaintiffs’ allegations, and in so doing, they can lay out a defense.

If relying upon information supplied in a recent report, there are quite a number of Zoloft cases in the MDL, and therefore each of these cases will necessitate address in the defense’s response. A Florida attorney who sits on the Plaintiffs’ Steering Committee (PSC), Bryan F. Aylstock, recently submitted a report late last year regarding the status of the Zoloft MDL. The legal journal, The Madison-St. Clair Record, stated that according to information contained in Alystock’s report, there are over 250 cases that have been consolidated into the Zoloft MDL.*

Plaintiffs in the Zoloft MDL have filed lawsuits against Pfizer, the manufacturer of Zoloft, claiming that the antidepressant drug, classified as a selective serotonin re-uptake inhibitor (SSRI), causes birth defects in newborn children when taken by women during pregnancy.

In a separate Zoloft lawsuit being heard in the Wayne County Circuit Court in West Virginia, nineteen plaintiffs, who are the children of mothers who claimed to have taken Zoloft during pregnancy, filed their lawsuit alleging that exposure to Zoloft in the womb resulted in the development of their birth defects.

According to the legal journal, The West Virginia Record, the plaintiffs identified these Zoloft linked birth defects as heart defects, such as atrial septal defects and holes in the heart, persistent pulmonary hypertension of the newborn (PPHN), skull and facial deformations, and a number of other congenital birth defects related to Zoloft exposure in utero.*

Lawyers at Carey Danis & Lowe are currently evaluating Zoloft cases, and they are offering legal consultations to those individuals who claim to have been harmed by the use of Zoloft during pregnancy. For more information about filing a Zoloft lawsuit, and specifically one related to Zoloft and birth defects, contact a lawyer at Carey Danis & Lowe by calling 800-721-2519.

The Injurious Link Between SSRI Antidepressants and Birth Defects

By | Antidepressant, Pharmaceutical litigation, Uncategorized

Published September 13, 2012 on Carey & Danis

The Injurious Link Between SSRI Antidepressants and Birth DefectsA grave conundrum is presented to women who suffer from depression during pregnancy. There are significant mental and physical health issues that must be considered in regards to medicating with a selective serotonin re-uptake inhibitor (SSRI) antidepressant such as Celexa, Lexapro, Luvox, Symbyax, Paxil, Zoloft, or Prozac while pregnant. Ending use of an SSRI antidepressant during pregnancy poses a risk to the mother’s mental health as well as to the unborn child, depending on when discontinuance of the medication occurs.

If an SSRI antidepressant was taken by the pregnant mother into the third trimester, it has been discovered that these antidepressant medications leach through the placental sack, thus exposing the unborn child to the drugs, often causing a chemical attachment resulting in withdrawal upon the child’s birth or the mother’s sudden termination of SSRI use.Signs of withdrawal in the newborn child are irritable mood, breathing complications, trembling, feeding problems, and hypoglycemia.

In recognition of these withdrawal symptoms in newborn children, the U.S. Food and Drug Administration (FDA) in 2004 released a warning in regards to the use of SSRI antidepressants by pregnant women in their third trimester. In their statement, the FDA made the recommendation that pregnant women medicating with an SSRI antidepressant be placed on a schedule which over time would gradually lower their dosage of an antidepressant.

Though this FDA warning and recommendation was targeted at the prevention of withdrawal symptoms in the newborn child, such near termination of SSRI antidepressant use by the pregnant mother was seen to cause serious mental health issues including a severe episode of postpartum depression. Drug withdrawal is not the only source of suffering inflicted on an unborn child exposed to SSRI antidepressants.

Epidemiology magazine examined in their May 2012 issue a recent study on the health of pregnant mothers using SSRI antidepressants. The study found that there is a significant link between the use of an SSRI antidepressant and pre-term delivery. In this specific study led by the Yale School of Public Health, the SSRI under examination was Paxil. Use of Paxil and other SSRI antidepressants while pregnant have also been linked to a number of other birth defects that cause an undue amount of suffering for a newborn child. These SSRI-linked birth defects include Persistent Pulmonary Hypertension of the Newborn (PPHN), omphalocele, craniosynostosis, atrial septal defects, and ventricular septal defects.

If an SSRI antidepressant was used during pregnancy and a newborn child suffered from a birth defect, compensation for such unfair suffering is due. Contact a knowledgeable pharmaceutical product liability litigation attorney at Carey Danis & Lowe for more information about filing a lawsuit against the manufacturers of Celexa, Lexapro, Luvox, Symbyax, Paxil, Zoloft, or Prozac.

Paxil Lawsuit Report

By | Paxil, Pharmaceutical litigation, Uncategorized

Published May 11, 2012 

Paxil Lawsuit News – 5/11/2012: Paxil may be linked to serious negative side effects. If you took Paxil and believe you suffered negative side effects as a result, contact us today so that we can make arrangements for a free consultation with a law firm that is investigating cases related to the side effects of Paxil.

Paxil Lawsuit: Families are continuing to file lawsuits against Paxil because of the occurrence of side effects from Paxil. Paxil is known as an anti-depressant, specifically a selective serotonin reuptake inhibitor (SSRI). There are different chemicals in your brain and SSRIs work to prevent the nerve cells from reabsorbing serotonin, thus making serotonin in the brain more available. It is believed by some that an imbalance of chemicals is the cause of depression and one available treatment is prescribing SSRIs because serotonin is essential to mood enhancement.

While SSRIs were first prescribed to depressed patients because of the reduced amount of side effects when compared to previous generations of anti-depressants, the side effects of Paxil can be extremely dangerous. Of particular concern is Paxil and pregnancy.

Paxil Lawsuit: Taking Paxil while pregnant can affect the development of the fetus. This then results in the Paxil bad side effects. Taking Paxil during the first trimester is especially dangerous. When babies are exposed to Paxil during the first trimester, they may be born with heart problems such as atrial or ventricular septal defects.

These defects are holes in the wall that separates the heart chambers. When this heart problem exists, it makes the organ work harder than it should. It is possible that over time this defect may correct itself, but may be so severe that it will require surgery. Paxil Lawsuit

Another negative Paxil side effect includes abnormalities in the development of the abdomen (omphalocele). A type of abdominal wall defect linked to the use of Paxil is when the intestines, liver and other organs stay outside the abdomen in a sac. In a Paxil baby, the muscles in the abdominal wall (umbilical ring) do not close properly.

Once the baby is born and doing well, this side effect of Paxil will require corrective surgery. This surgery creates a cavity inside the abdomen to contain the intestinal contents. If your child has suffered from a Paxil birth defect, contact a Paxil lawyer for a consultation.

Attorney Jeff Lowe Speaks about Paxil Birth Defects

By | Paxil, Pharmaceutical litigation, Uncategorized

Posted April 27, 2010 

St. Louis, MO: Women who took Paxil during the first trimester of pregnancy and whose children were born with birth defects should consider speaking with an attorney about their options. Jeff Lowe, a partner at Carey Danis & Lowe, says serious birth defects have been linked to the use of Paxil during pregnancy.

Attorney Jeff Lowe Speaks about Paxil Birth Defects “The cases that we’re handling are birth defects that occurred primarily for woman who took Paxil during the first trimester,” Lowe says. “The primary birth defects are Persistent Pulmonary Hypertension of the Newborn (PPHN) and cardiac defects. Those cardiac defects are mainly atrial or septal defects—holes in the heart.”

That does not mean that babies born with other birth defects are excluded from a potential lawsuit. Pregnant women who took any antidepressants from a class of drugs known as selective serotonin reuptake inhibitors (SSRIs, a class that includes Paxil) or serotonin-norepinephrine reuptake inhibitors (SNRIs, a class that includes Effexor) and whose babies were born with birth defects may want to consider speaking to an attorney about their options.

So far the medical literature has made the strongest link between use of certain antidepressants during the first trimester and an increased risk of PPHN or cardiac defects.

“There were studies looking at SSRIs and the early literature didn’t see a connection [between SSRIs and birth defects],” Lowe says. “Then some studies began finding a connection between Paxil and birth defects such as PPHN and cardiac defects. GlaxoSmithKline [Paxil’s manufacturer] had a database they were keeping that was based on their own studies. In 2006, they published their online database, which demonstrated a higher risk in major malformations for infants exposed to Paxil in the first trimester. Additional independent peer reviewed studies confirmed the link.

“Paxil’s warning was changed in 2005 [to include the risk of birth defects]. There was an FDA warning letter issued on December 8, 2005 and a Dear Doctor letter issued in September 2005.”

The good news for potential plaintiffs is that the statute of limitations is not as much of an issue in Paxil birth defect cases as in other situations, because the person most affected by the Paxil is the child. In all states, according to Lowe, “the statute of limitations doesn’t begin to run for a minor until the minor is either 18 to 21 years old, depending on state law, so there isn’t a statute of limitations issue for most children born with birth defects as a result of their mothers taking Paxil.”